MichaletsEL, PoundersCL, HollisSJ, SutherlandS. Outcomes associated with AUC24/MIC nomogram dosing of vancomycin. Ann Pharmacother2011; 45:687–9. DOI 10.1345/aph.1P495
2.
RybakMJ, LomaestroBM, RotschaferJC. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis2009; 49:325–7.
3.
Moise-BroderPA, ForrestA, BirminghamMC, SchentagJJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet2004; 43:925–42.
4.
ProostJH, MeijerDK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Corn-put Biol Med1992; 22:155–63.
5.
van der MeerAF, MarcusMA, TouwDJ, ProostJH, NeefC. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit2011; 33:133–46.
6.
RybakMJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis2006; 42(suppl 1):S35–9.
7.
Vance-BryanK, GuayDR, GillilandSS, RodvoldKA, RotschaferJC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother1993; 37:436–40.
